Nasdaq:US$19.45 (+0.67) | HKEX:HK$30.20 (+0.30) | AIM:£3.05 (+0.08)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.